Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
9.4
4.8
Journals
Biomolecules
Special Issues
Risk Prediction Tools and Biomarkers in Gynaecological Cancer
share announcement

Risk Prediction Tools and Biomarkers in Gynaecological Cancer

A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Molecular Biomarkers".

Deadline for manuscript submissions: closed (20 May 2022) | Viewed by 10408

Special Issue Editors

Dr. Jure Knez

E-Mail Website
Guest Editor
Department of Gynaecology and Obstetrics, Faculty of Medicine University of Maribor, Taborska ulica 8, 2000 Maribor, Slovenia
Interests: endometrial cancer; endometriosis; biomarkers in gynaecology; ultrasound; gynaecological oncology
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Iztok Takač

E-Mail Website
Guest Editor
Divison of Gynecology and Perinatology, University Medical Centre Maribor, 2000 Maribor, Slovenia
Interests: gynecologic oncology; ultrasound; breast cancer
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This planned Special Issue of Biomolecules is dedicated to revealing new findings in the diagnostics and management of women with gynaecological cancer. The issue will focus specifically on the new tools that have emerged recently and allow for better diagnostics and management of women based on specific tumour risk.  

Discoveries of new molecular biomarkers are changing the approach to management of women with gynaecological cancer today. With the implementation of precision medicine, management can be focused, precise, and based on the tumour biology potential. This allows for better implementation of novel treatment possibilities, such as immune checkpoint inhibitors, antiangiogenic agents or PI3K/mTOR inhibitors. It is vital to provide the most effective guided therapy to women with high-risk tumours. On the other hand, it is also crucial to consider the quality of life and identify women that would benefit from more conservative management approaches, less radical surgery, and suffer fewer complications related to the applied treatment.

We welcome submissions that cover any relevant topic in the areas of improving the current risk prediction models or new biomarkers that can be used to predict the risk or guide management in women with gynaecological cancer.

Dr. Jure Knez
Prof. Dr. Iztok Takač
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Gynaecological cancer
  • Biomarkers
  • Precision medicine
  • Risk prediction

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

12 pages, 1871 KiB  
Article
Overweight as a Favorable Clinical Biomarker for Checkpoint Inhibitor Therapy Response in Recurrent Gynecologic Cancer Patients
by Thomas Bartl, Arina Onoprienko, Gerda Hofstetter, Leonhard Müllauer, Nina Poetsch, Thorsten Fuereder, Paul Kofler, Stephan Polterauer and Christoph Grimm
Biomolecules 2021, 11(11), 1700; https://doi.org/10.3390/biom11111700 - 16 Nov 2021
Cited by 5 | Viewed by 2675
Abstract
Despite increasing clinical interest in adapting checkpoint inhibitor (CPI) therapies for patients with gynecologic malignancies, no accurate clinical biomarkers to predict therapy response and prognosis are currently available. Therefore, we aimed to assess the predictive and prognostic value of pretherapeutic body mass index [...] Read more.
Despite increasing clinical interest in adapting checkpoint inhibitor (CPI) therapies for patients with gynecologic malignancies, no accurate clinical biomarkers to predict therapy response and prognosis are currently available. Therefore, we aimed to assess the predictive and prognostic value of pretherapeutic body mass index (BMI) for recurrent gynecologic cancer patients as previously validated for other solid tumors. We evaluated patients with programmed cell death ligand 1 (PD-L1) positive and, in endometrial cancer, also mismatch repair deficient (MMR) gynecologic malignancies, who received the PD-1 inhibitor pembrolizumab as monotherapy (200 mg fixed-dose q3 w) from 2017 to 2020 (n = 48). Thirty-six patients receiving at least four courses were included in the final analysis. Associations between a BMI increase per 5 kg/m2 and overall response rate (ORR; complete + partial response), disease control rate (DCR; ORR + stable disease), progression-free (PFS), and overall survival (OS) were assessed. An elevated BMI was univariately associated with ORR (OR 10.93 [CI 2.39–49.82], p = 0.002), DCR (OR 2.19 [CI 0.99–4.83], p = 0.048), prolonged PFS (HR 1.54 [CI 1.03–2.34], p = 0.038), and OS (HR 1.87 [CI 1.07–3.29], p = 0.028). All results could be confirmed in the multivariate analyses. Pretherapeutic BMI therefore appears to be a promising readily available biomarker to identify patients with PD-L1-positive and/or MMR-deficient gynecologic malignancies who could particularly benefit from CPI treatment. Full article
(This article belongs to the Special Issue Risk Prediction Tools and Biomarkers in Gynaecological Cancer)
►▼ Show Figures

Figure 1

12 pages, 1049 KiB  
Article
Toll-like Receptor 2 as a Marker Molecule of Advanced Ovarian Cancer
by Małgorzata Sobstyl, Paulina Niedźwiedzka-Rystwej, Rafał Hrynkiewicz, Dominika Bębnowska, Izabela Korona-Głowniak, Marcin Pasiarski, Barbara Sosnowska-Pasiarska, Jolanta Smok-Kalwat, Stanisław Góźdź, Anna Sobstyl, Wojciech Polkowski, Jacek Roliński and Ewelina Grywalska
Biomolecules 2021, 11(8), 1205; https://doi.org/10.3390/biom11081205 - 13 Aug 2021
Cited by 5 | Viewed by 2170
Abstract
Ovarian cancer is a global problem that affects women of all ages. Due to the lack of effective screening tests and the usually asymptomatic course of the disease in the early stages, the diagnosis is too late, with the result that less than [...] Read more.
Ovarian cancer is a global problem that affects women of all ages. Due to the lack of effective screening tests and the usually asymptomatic course of the disease in the early stages, the diagnosis is too late, with the result that less than half of the patients diagnosed with ovarian cancer (OC) survive more than five years after their diagnosis. In this study, we examined the expression of TLR2 in the peripheral blood of 50 previously untreated patients with newly diagnosed OC at various stages of the disease using flow cytometry. The studies aimed at demonstrating the usefulness of TLR2 as a biomarker in the advanced stage of ovarian cancer. In this study, we showed that TLR2 expression levels were significantly higher in women with more advanced OC than in women in the control group. Our research sheds light on the prognostic potential of TLR2 in developing new diagnostic approaches and thus in increasing survival in patients with confirmed ovarian cancer. Full article
(This article belongs to the Special Issue Risk Prediction Tools and Biomarkers in Gynaecological Cancer)
►▼ Show Figures

Figure 1

Review

Jump to: Research

14 pages, 1097 KiB  
Review
Diagnostic and Therapeutic Values of Angiogenic Factors in Endometrial Cancer
by Luka Roškar, Irena Roškar, Tea Lanišnik Rižner and Špela Smrkolj
Biomolecules 2022, 12(1), 7; https://doi.org/10.3390/biom12010007 - 21 Dec 2021
Cited by 12 | Viewed by 4680
Abstract
Endometrial cancer (EC) is the most frequent gynecological malignancy in developed countries and requires a relatively invasive diagnostic evaluation and operative therapy as the primary therapeutic approach. Angiogenesis is one of the main processes needed for cancer growth and spread. The production of [...] Read more.
Endometrial cancer (EC) is the most frequent gynecological malignancy in developed countries and requires a relatively invasive diagnostic evaluation and operative therapy as the primary therapeutic approach. Angiogenesis is one of the main processes needed for cancer growth and spread. The production of angiogenic factors (AFs) appears early in the process of carcinogenesis. The detection of AFs in plasma and tissue and a better understanding of the angiogenic properties of EC may contribute not only to earlier but also more specific diagnosis and consequently tailored and individual therapeutic approaches. AFs and their receptors also have high potential as binding sites for targeted cancer therapy. In this review, we discuss angiogenesis in EC and the characteristics of the AFs that most contribute to angiogenesis in EC. We also highlight therapeutic strategies that target angiogenesis as potential EC therapy. Full article
(This article belongs to the Special Issue Risk Prediction Tools and Biomarkers in Gynaecological Cancer)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop